期刊文献+

RAS signaling pathways, mutations and their role in colorectal cancer 被引量:8

下载PDF
导出
摘要 Two of the main cellular pathways in which the RAS protein operates are the mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K) pathways. In a normal cell, these are important in controlling several functions, such as cell growth and survival. It becomes self-evident that these events will be disrupted in a malignant cell with a deregulated MAPK or PI3K pathway. Mutations in genes involved in these pathways and interacting with RAS, as well as RAS itself will be discussed. The second part of this review concentrates on how crucial RAS signaling is in colorectal cancer progression, with references to treatment response and prognosis when RAS or other related mutations are present. Two of the main cellular pathways in which the RAS protein operates are the mitogen-activated protein kinases (MAPK) and phosphoinositide-3 kinase (PI3K) pathways. In a normal cell, these are important in controlling several functions, such as cell growth and survival. It becomes self-evident that these events will be disrupted in a malignant cell with a deregulated MAPK or PI3K pathway. Mutations in genes involved in these pathways and interacting with RAS, as well as RAS itself will be discussed. The second part of this review concentrates on how crucial RAS signaling is in colorectal cancer progression, with references to treatment response and prognosis when RAS or other related mutations are present.
出处 《World Journal of Gastrointestinal Oncology》 SCIE CAS 2013年第5期97-101,共5页 世界胃肠肿瘤学杂志(英文版)(电子版)
关键词 Genes RAS COLORECTAL NEOPLASMS Thera-peutics MITOGEN-ACTIVATED protein KINASE signaling system Genes RAS Colorectal neoplasms Thera-peutics Mitogen-activated protein kinase signaling system
  • 相关文献

参考文献30

  • 1Reuter CW,Morgan MA,Bergmann L.Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies. Blood . 2000
  • 2Fearon ER;Vogelstein B.A genetic model for colorectal tumorigenesis,1990(05).
  • 3Shaw RJ,Cantley LC.Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature . 2006
  • 4Ortiz-Vega S,Khokhlatchev A,Nedwidek M,et al.The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Norel. Oncegene . 2002
  • 5Schuell B,Gruenberger T,Scheithauer W,et al.HER2/neuprotein expression in colorectal cancer. BMC Cancer . 2006
  • 6Baldus SE,Schaefer KL,Engers R,et al.Prevalence and heterogeneity of KRAS,BRAF,and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clinical Cancer Research . 2010
  • 7Vakiani E,Solit D B.KRAS and BRAF: Drug targets and predictive biomarkers. Journal of Paleopathology . 2011
  • 8Donninger H,Vos M D,Clark G J.The RASSF1A tumor suppressor. Journal of Cell Science . 2007
  • 9Markowitz SD,Bertagnolli MM.Molecular origins of cancer:Molecular basis of colorectal cancer. The New England Journal of Medicine . 2009
  • 10Oki,E,Oda,S,Maehara,Y,Sugimachi,K.Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair. Oncegene . 1999

共引文献3

同被引文献27

引证文献8

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部